Guardian Wealth Advisors LLC NC Acquires 453 Shares of Medtronic plc (NYSE:MDT)

Guardian Wealth Advisors LLC NC increased its holdings in Medtronic plc (NYSE:MDT) by 15.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,371 shares of the medical technology company’s stock after purchasing an additional 453 shares during the period. Guardian Wealth Advisors LLC NC’s holdings in Medtronic were worth $269,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Mainstream Capital Management LLC acquired a new position in Medtronic during the 4th quarter worth $26,000. Rakuten Securities Inc. raised its position in shares of Medtronic by 753.8% during the fourth quarter. Rakuten Securities Inc. now owns 333 shares of the medical technology company’s stock valued at $27,000 after buying an additional 294 shares during the last quarter. Stephens Consulting LLC raised its position in shares of Medtronic by 145.7% during the fourth quarter. Stephens Consulting LLC now owns 344 shares of the medical technology company’s stock valued at $27,000 after buying an additional 204 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of Medtronic during the fourth quarter valued at about $31,000. Finally, Chapman Financial Group LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $33,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of Medtronic stock opened at $83.47 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.39 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $107.05 billion, a price-to-earnings ratio of 25.37, a P/E/G ratio of 2.22 and a beta of 0.81. Medtronic plc has a 1-year low of $75.96 and a 1-year high of $96.25. The firm’s 50-day moving average price is $86.76 and its two-hundred day moving average price is $86.76.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.03. The firm had revenue of $8.29 billion for the quarter, compared to analysts’ expectations of $8.33 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. On average, equities analysts predict that Medtronic plc will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were paid a dividend of $0.70 per share. The ex-dividend date was Friday, March 28th. This represents a $2.80 annualized dividend and a yield of 3.35%. Medtronic’s dividend payout ratio is 85.11%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research report on Wednesday, February 19th. Robert W. Baird upped their price objective on shares of Medtronic from $90.00 to $91.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Citigroup raised shares of Medtronic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $92.00 to $107.00 in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Medtronic in a research report on Wednesday, February 19th. Finally, UBS Group increased their price target on shares of Medtronic from $85.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $96.14.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.